Skip to main content
SpringerLink
Log in

Is Clonidine an Effective Smoking Cessation Therapy?

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Catapres® Approved Product Information. Physicians’ Desk Reference 1994. 48th ed. Oradell, NJ: Medical Economics Co., 1994

    Google Scholar 

  2. Bredfeldt RC, Sutherland JE, Kruse JE. Efficacy of transdermal clonidine for headache prophylaxis and reduction of narcotic use in migraine patients. J Fam Pract 1989; 29: 153–6

    PubMed  CAS  Google Scholar 

  3. Edington RF, Chagnon J-P, Steinburg WM. Clonidine (dixarit) for menopausal flushing. Can Med Assoc J 1980; 123: 23–5

    PubMed  CAS  Google Scholar 

  4. Ginsburg J, O’Reilly B, Swinhoe J. Effect of oral clonidine on human cardiovascular responsiveness: a possible explanation of the therapeutic action of the drug in menopausal flushing and migraine. Br J Obstet Gynaecol 1985; 92: 1169–75

    Article  PubMed  CAS  Google Scholar 

  5. Leckman JF, Detlor J, Harcherik DF, et al. Short- and long-term treatment of Tourette’s syndrome with clonidine: a clinical perspective. Neurology 1985; 35: 343–51

    Article  PubMed  CAS  Google Scholar 

  6. Gold MS. Opiate addiction and the locus coeruleus. Psych Clin North Am 1993; 16: 61–73

    CAS  Google Scholar 

  7. Manhem P, Nilsson LH, Moberg A, et al. Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin-aldosterone system, and clinical symptoms. Alcohol Clin Exp Res 1985; 9: 238–43

    Article  PubMed  CAS  Google Scholar 

  8. Glassman AH, Jackson WK, Walsh BT, et al. Cigarette craving, smoking withdrawal and clonidine. Science 1984; 226: 864–6

    Article  PubMed  CAS  Google Scholar 

  9. Ornish SA, Zisook S, McAdams LA. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. Arch Intern Med 1988; 148: 2027–31

    Article  PubMed  CAS  Google Scholar 

  10. Wei H, Young D. Effect of clonidine on cigarette cessation and in the alleviation of withdrawal symptoms. Br J Addict 1988; 83: 1221–6

    Article  PubMed  Google Scholar 

  11. Franks P, Harp J, Bell B. Randomised, controlled trial of clonidine for smoking cessation in a primary care setting. JAMA 1989; 262: 3011–3

    Article  PubMed  CAS  Google Scholar 

  12. Prochazka AV, Petty TL, Nett L, et al. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med 1992; 152: 2065–9

    Article  PubMed  CAS  Google Scholar 

  13. Gourlay SG, Forbes A, Marriner T, et al. A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharm Ther 1994; 55: 64–9

    Article  CAS  Google Scholar 

  14. Grimaldi B, Demaria C, Loufrani E, et al. Le sèvrage tabagique: resultats de plusieurs études controlées méthode active-placebo avec un prise en charge globale dans le cadre d’une consultation anti-tabac. Sem Hop 1987; 63: 3373–5

    Google Scholar 

  15. Davison R, Kaplan K, Fintel D, et al. The effect of clonidine on the cessation of cigarette smoking. Clin Pharmacol Ther 1988; 44: 265–7

    Article  PubMed  CAS  Google Scholar 

  16. Glassman AH, Stetner F, Walsh T, et al. Heavy smokers, smoking cessation, and clonidine. JAMA 1988; 259: 2863–6

    Article  PubMed  CAS  Google Scholar 

  17. Villagra VG, Rosenberger JL, Girolami S. Transdermal clonidine for smoking cessation: a randomised, double-blind, placebo-controlled trial. Circulation 1989; 80 Suppl. 2: II–58

    Google Scholar 

  18. Glassman A, Covey L, Dalack G, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993; 54: 670–9

    Article  PubMed  CAS  Google Scholar 

  19. Hilleman DE, Mohiuddin SM, Delcore MG, et al. Randomized, controlled trial of transdermal clonidine for smoking cessation. Ann Pharmacother 1993; 27: 1025–8

    PubMed  CAS  Google Scholar 

  20. Dollery CT, Davies DS, Draffan GH, et al. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharm Ther 1976; 19: 11–7

    CAS  Google Scholar 

  21. Anavekar SN, Howes LG, Jarrott B, et al. Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy. J Clin Pharmacol 1989; 29: 321–6

    PubMed  CAS  Google Scholar 

  22. Conway EL, Anavekar SN, Howes LG, et al. Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. Hypertension 1992; 32: 427–3

    CAS  Google Scholar 

  23. Davies DS, Wing LMH, Reid JL, et al. Pharmacokinetics and concentration-effect relationships of intravenous and oral clonidine. Clin Pharmacol Ther 1977; 21: 593–601

    PubMed  CAS  Google Scholar 

  24. Frisk-Holmberg M, Paalzow L, Edlund PO. Clonidine kinetics in man — evidence for dose dependency and changed pharmacokinetics during chronic therapy. Br J Clin Pharmacol 1981; 12: 653–8

    Article  PubMed  CAS  Google Scholar 

  25. Arndts D, Doevendans J, Kirsten R, et al. New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man. Eur J Clin Pharm 1983; 24: 21–30

    Article  CAS  Google Scholar 

  26. MacGregor TR, Relihan GL, Keims JJ. Pharmacokinetics of oral sustained release clonidine in humans. Arzneimittel Forschung 1985; 35: 440–6

    PubMed  CAS  Google Scholar 

  27. Shaw JE. Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route. Am Heart J 1984; 108: 217–23

    Article  PubMed  CAS  Google Scholar 

  28. Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. Clin Pharmacokinet 1988; 14: 287–310

    Article  PubMed  CAS  Google Scholar 

  29. Fujimura A, Ebihara A, Ohashi K, et al. Pharmacokinetics and pharmacodynamics of a new transdermal clonidine, M-5041T, in healthy subjects. J Clin Pharmacol 1993; 33: 1192–200

    PubMed  CAS  Google Scholar 

  30. Fujimura A, Ebihara A, Ohashi K, et al. Comparison of the pharmacokinetics of oral (catapres) and transdermal (M-5041T) clonidine in healthy subjects. J Clin Pharmacol 1994; 34: 260–5

    PubMed  CAS  Google Scholar 

  31. MacGregor TR, Matzek KM, Keirns JJ, et al. Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther 1985; 38: 278–84

    Article  PubMed  CAS  Google Scholar 

  32. Rominger KL, Schafer E, Vrecko HG, et al. Pharmacokinetics of clonidine following intravenous administration of high doses for the treatment of delirium tremens. Arzneimittel Forschung 1991; 41: 399–401

    PubMed  CAS  Google Scholar 

  33. Fauler J, Verner LJ. The pharmacokinetics of clonidine in high dosage. Eur J Clin Pharm 1993; 45: 165–7

    Article  CAS  Google Scholar 

  34. Lowenthal DT. Pharmacokinetics of clonidine. J Cardiovasc Pharmacol 1980; 2 Suppl. 1: S29–37

    Article  PubMed  Google Scholar 

  35. Davies DS, Wing LMH, Reid JL, et al. Pharmacokinetics and pharmacodynamic studies with clonidine in normal subjects. Clin Sci Mol Med 1976; 51: 639s–40s

    Google Scholar 

  36. Wing LMH, Reid JL, Davies DS, et al. Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol 1977; 12: 463–9

    Article  PubMed  CAS  Google Scholar 

  37. Keranen A, Nykänen S, Taskinen J. Pharmacokinetics and side-effects of clonidine. Eur J Clin Pharmacol 1978; 13: 97–101

    Article  PubMed  CAS  Google Scholar 

  38. Frisk-Holmberg M, Edlund PO, Paalzow L. Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients. Br J Clin Pharmacol 1978; 6: 227–32

    Article  PubMed  CAS  Google Scholar 

  39. Anavekar SN, Jarrott M, Toscano M, et al. Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. Eur J Pharmacol 1982; 23: 1–5

    Article  CAS  Google Scholar 

  40. van Essen EJ, Ploeger EJ, Houben JJG. Pharmacokinetics of clonidine after epidural administration in surgical patients: lack of correlation between plasma concentration and analgesia and blood pressure changes. Acta Anaesthesiol Scand 1992; 36: 300–4

    Article  PubMed  Google Scholar 

  41. Porchet HC, Piletta P, Dayer P. Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. Eur J Clin Pharm 1992; 42: 655–62

    Article  CAS  Google Scholar 

  42. Lonnqvist PA, Bergendahl HTG, Eksborg S. Pharmacokinetics of clonidine after rectal administration in children. Anesthesiology 1994; 81: 1097–101

    Article  PubMed  CAS  Google Scholar 

  43. Lowenthal DT, Affrime MB, Meyer A, et al. Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function. Chest 1983; 83 (2 Suppl.): 387s–90s

    Google Scholar 

  44. Hartikainen-Sorri AL, Heikkinen JE, Koivisto M. Pharmacokinetics of clonidine during pregnancy and nursing. Obstet Gynecol 1987; 69: 598–600

    PubMed  CAS  Google Scholar 

  45. De Vos H, Bricca G, De Keyser J, et al. Imidazoline receptors, non-adrenergic idazoxan binding sites and α2-adrenoreceptors in the human central nervous system. Neuroscience 1994; 59: 589–98

    Article  PubMed  Google Scholar 

  46. Svensson TH. Peripheral, autonomic regulation of locus coeruleus noradrenergic neurones in brain: putative implications for psychiatry and psychopharmacology. Psychopharmacology 1987; 92: 1–7

    Article  PubMed  CAS  Google Scholar 

  47. Amaral DG, Sinnamon HM. The locus coeruleus: neurobiology of a central noradrenergic nucleus. Prog Neurobiol 1977; 9: 147–96

    Article  PubMed  CAS  Google Scholar 

  48. Rassmussen K, Beitner-Johnson DB, Krystal JH, et al. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J Neurosci 1990; 10: 2308–17

    Google Scholar 

  49. Redmond DE. Alterations in the function of the nucleus locus coeruleus: a possible model for studies of anxiety. In: Hanin I, Usdin E, editors. Animal models in psychiatry and neurology. New York: Pergamon Press, 1977: 293–305

    Google Scholar 

  50. Tung C-S, Ugendo L, Grenhoff J, et al. Peripheral induction of burst firing in locus coeruleus neurons by nicotine mediated via excitatory amino acids. Synapse 1989; 4: 313–8

    Article  PubMed  CAS  Google Scholar 

  51. Tibirica E, Feldman J, Mermet C, et al. An imidazoline-specific mechanism for the hypotensive effect of clonidine: a study with yohimbine and idazoxan. J Pharm Exp Ther 1990; 256: 606–13

    Google Scholar 

  52. Liu N, Bonnet F, Delaunay L, et al. Partial reversal of the effects of extradural clonidine by oral yohimbine in postoperative patients. Br J Anaesth 1993; 70: 515–8

    Article  PubMed  CAS  Google Scholar 

  53. Thollander M, Hellstrom PM, Svensson TH. Suppression of castor oil-induced diarrhoea by alpha 2-adrenoreceptor agonists. Aliment Pharmacol Ther 1991; 5: 255–62

    Article  PubMed  CAS  Google Scholar 

  54. Anderson RJ, Hart GR, Crumpler CP, et al. Clonidine overdose: report of six cases and review of the literature. Ann Emerg Med 1981; 10: 107–12

    Article  PubMed  CAS  Google Scholar 

  55. Domino LE, Domino SE, Stockstill MS. Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose. Br J Clin Pharm 1986; 21: 71–4

    Article  CAS  Google Scholar 

  56. Ishii K, Yamamoto S, Kato R. Increase in insulin response to glucose in the rat chronically treated with clonidine. Arch Pharmacol 1985; 328: 253–7

    Article  CAS  Google Scholar 

  57. Ferlito S, Indelicato G, Di Vicenzo, et al. Effect of clonidine on glucose, insulin and glucagon responses to a protein meal in type 2 diabetics. J Endocrinol Invest 1985; 8: 185–7

    PubMed  CAS  Google Scholar 

  58. Barbieri C, Caldara R, Testori G, et al. Oral glucose tolerance and insulin response after one week’s clonidine treatment in hypertensive patients. Acta Diabetol Latina 1981; 18: 59–63

    Article  CAS  Google Scholar 

  59. Klein C, Morton N, Kelley S, et al. Transdermal clonidine therapy in elderly mild hypertensives: effects on blood pressure, plasma norepinephrine and fasting plasma glucose. J Hypertens 1985; 3 Suppl.: S81–4

    Article  CAS  Google Scholar 

  60. Webster WB, McConnaughey MM. Clonidine and glucose intolerance. Drug Intell Clin Pharmacy 1982; 16: 325–8

    Google Scholar 

  61. Hatsukumi D, Hughes JR, Pickens R, et al. Tobacco withdrawal symptoms: an experimental analysis. Psychopharmacology 1984; 84: 231–6

    Article  Google Scholar 

  62. Benowitz NL. Pharmacologic aspects of smoking. N Engl J Med 1988; 319: 1318–30

    Article  PubMed  CAS  Google Scholar 

  63. American Psychiatric Association. Diagnostic and statistical manual of psychiatric disorders. 4th ed. (DSM-IV). Washington (DC): American Psychiatric Association, 1994

    Google Scholar 

  64. Garty M, Ben-Zvi Z, Hurwitz A. Interaction of clonidine and morphine with lidocaine in mice and rats. Toxicol Appl Pharmacol 1989; 101: 255–60

    Article  PubMed  CAS  Google Scholar 

  65. Jounela AJ, Kanniainen E, Lilja M. Interaction between clonidine and alpha blockers. Clin Cardiol 1985; 8: 641–2

    Article  PubMed  CAS  Google Scholar 

  66. Plouin PF, Degoulet P, Ferme I, et al. Clonidine, acebutalol, and their interaction in essential hypertension: effects on blood pressure and the control of water and electrolyte balance. Eur Heart J 1983 Nov; 4 Suppl. G: 7–11

    PubMed  Google Scholar 

  67. Gutkind JS, Enero MA. Different pharmacological interaction of clonidine and guanabenz with antidepressive drugs. Clin Exp Hypertens A 1987; 9: 1531–47

    Article  PubMed  CAS  Google Scholar 

  68. Ghodse H, Myles J, Smith SE. Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction. Br J Psych 1994; 165: 370–4

    Article  CAS  Google Scholar 

  69. Svensson TH. Clonidine in abstinence reactions: basic mechanisms. Acta Psychiatr Scand 1986; 327 Suppl.: 19–42

    CAS  Google Scholar 

  70. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320–31

    Article  Google Scholar 

  71. Bulpitt CJ. Meta-analysis. Lancet 1988; 2: 93–4

    Article  PubMed  CAS  Google Scholar 

  72. Gourlay SG, Forbes A, Marriner T, et al. A prospective study of factors predicting smoking cessation using transdermal nicotine therapy. BMJ 1994; 309: 842–6

    Article  PubMed  CAS  Google Scholar 

  73. Coambs RB, Li S, Kozlowski LT. Age interacts with heaviness of smoking in predicting success in cessation of smoking. Am J Epidemiol 1992; 135: 240–6

    PubMed  CAS  Google Scholar 

  74. Fagerström KO. Measuring the degree of physical dependence to tobacco smoking with reference to individualisation of treatment. Addict Behav 1978; 3: 235–41

    Article  PubMed  Google Scholar 

  75. Transdermal nicotine study group. Transdermal nicotine for smoking cessation. JAMA 1991; 266: 3133–8

    Article  Google Scholar 

  76. Russell MAH, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. BMJ 1993; 306: 1308–12

    Article  PubMed  CAS  Google Scholar 

  77. Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. BMJ 1993; 306: 1304–8

    Article  Google Scholar 

  78. Tønnesen P, Fryd V, Hansen M, et al. Effect of nicotine chewing gum in combination with group counselling on the cessation of smoking. N Engl J Med 1988; 318: 15–8

    Article  PubMed  Google Scholar 

  79. Hughes JR, Gust SW, Keenan RM, et al. Nicotine vs placebo gum in general medical practice. JAMA 1989; 261: 1300–5

    Article  PubMed  CAS  Google Scholar 

  80. Sutherland G, Stapleton JA, Russell MAH, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324–9

    Article  PubMed  CAS  Google Scholar 

  81. Tønnesen P, Nørregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269: 1268–71

    Article  PubMed  Google Scholar 

  82. Fetrow CW, Hoyt JW, White TM. Clonidine patch: reservoir for abuse. J Clin Psych 1994; 55: 266

    CAS  Google Scholar 

  83. Report of the US Surgeon General. The health consequences of smoking: nicotine addiction. United States Department of Health and Human Services, 1988

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology and Experimental Therapeutics, University of California, UCSF Box 0898, San Francisco, California, 94143-0898, USA

    Steven G. Gourlay & Neal L. Benowitz

Authors
  1. Steven G. Gourlay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neal L. Benowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gourlay, S.G., Benowitz, N.L. Is Clonidine an Effective Smoking Cessation Therapy?. Drugs 50, 197–207 (1995). https://doi.org/10.2165/00003495-199550020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199550020-00001

Keywords

Search

Navigation